Company intelligence / Profile preview

Nanjing Jisheng Aoma Biopharmaceutical

Nanjing, Jiangsu, China

Ownership: Private
Development stage: Other

Overview

Jisheng Aoma is a clinical-stage biopharmaceutical company based in Nanjing, China, specializing in the discovery and development of innovative antibody-based therapeutics. The company focuses on oncology, leveraging its proprietary antibody engineering platforms to create next-generation monoclonal and bispecific antibodies. Its pipeline includes candidates targeting well-established pathways like PD-1/PD-L1 and VEGF, as well as novel combinations designed to overcome resistance in solid tumors. Jisheng Aoma aims to provide high-quality, affordable biologics for patients with unmet medical needs in the global market.

Therapeutic areas: Oncology
Modalities: Monoclonal antibodyBispecific monoclonal antibodyAntibodySmall molecule
Industry: Biotech

Beyond the preview

Go deeper on Nanjing Jisheng Aoma Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Nanjing Jisheng Aoma Biopharmaceutical.

Explore the full profile